The United Kingdom and the United States have reached a major commercial pact that will keep zero levies on UK drug products being sold in the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these crucial goods will be held at nothing for a period of three years.
This development is in response to recent threats to hike duties on branded drug products, with figures mentioned up to 100%.
"This agreement with the UK reinforces the worldwide climate for innovative medicines and brings much-needed equity to American-British pharmaceutical trade," a statement said.
Commercial Importance
Pharmaceuticals represent one of the UK's biggest exports to the US, which is by far the primary destination for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of September, the UK shipped drugs valued at £11.1bn to the US. This amount made up 17.4% of British export trade in that span.
"This deal protects employment, stimulates investment and facilitates the UK to establish itself as a global hub for medical research," a government official commented.
Specific British Pledges
The deal entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds were more than 20%.
Industry Background
The pact follows a ongoing row between the sector and the British authorities over medicine costs and approval rates.
This friction were exacerbated by arguments that US consumers were paying significantly more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
